Palantir was undervalued going into Q2, and its results prove it. Revenue rose 93% YoY and EBITDA 155%, and with estimates rising it entered earnings at under 45x NTM EBITDA, perhaps closer to 40x, too cheap for 90-95% revenue growth at 62% EBITDA margins. The sell side's 45-50% revenue CAGR for 2027-2030 looks achievable or even conservative, implying $25-30B of 2030 EBITDA or free cash flow before any acquisitions. x.com